國家衛生研究院 NHRI:Item 3990099045/11211
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857718      線上人數 : 766
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11211


    題名: Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma
    作者: Wang, WC;Hsu, YC;Shiao, HY;Hung, HC;Kuo, CC;Lee, JC;Hsu, TA;Hsieh, HP
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: According to the statistics from Ministry of Health and Welfare in Taiwan, non-Hodgkin's lymphoma is ranked as number nine on leading cause of cancer death toward both male and female people. In Taiwan, 85% non-Hodgkin's lymphoma patients belong to B cell lymphoma patients. In general, these kinds of blood diseases were treated by traditional chemotherapy or radiation therapy, but the results exert poor treatment effectiveness. In these years, scientists reported Bruton’s tyrosine kinase (BTK) is a key component in the B-cell receptor signal pathway regulating survival, activation, proliferation, and differentiation of B cells. Several studies demonstrated that BTK is overexpressed in several B cell lymphomas and BTK inhibitors may be useful in lymphoma patients. Hence, BTK inhibitors may constitute an exciting new generation of treatments for B cell lymphomas. In our effort to develop novel BTK inhibitors, BPRBK0005 was first identified as a BTK lead through screening our in house synthesized kinase inhibitors. We next sought in silico means to proceed further lead optimizations. A new series of furanopyrimidinecontaining derivatives were synthesized and evaluated against BTK enzyme- and cellbased assays. Among these, BPRBK0169 reveal excellent BTK inhibition with an IC50 value of 10 nM, calcium flux inhibition with an IC50 value of 11 nM, as well as up to 38-fold more potent antiproliferation in Ramos lymphoma cell line than the leading clinical drug, ibrutinib. Accordingly, it is considered a highly promising candidate for further development.
    日期: 2015-08
    關聯: Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180.
    Link to: https://www.acs.org/content/acs/en/meetings/national-meeting/about/meetings-archive.html
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000432475701334
    顯示於類別:[謝興邦] 會議論文/會議摘要
    [李靜琪] 會議論文/會議摘要
    [郭靜娟] 會議論文/會議摘要
    [王文傑] 會議論文/會議摘要

    文件中的檔案:

    檔案 大小格式瀏覽次數
    ISI000432475701334.pdf89KbAdobe PDF1113檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋